CD8A and neoplasm: Moreover, since the high number of CD8+ T cells at the tumor site is important for immunotherapy, especially using anti-PD1 Abs, LIF-neutralizing Abs in combination with anti-PD1Abs suppress tumor growth and prolong the survival of tumor-bearing hosts [64].